The 11 references without contexts in paper I. Snegireva I., K. Zatolochina E., M. Darmostukova A., R. Alyautdin N., B. Romanov K., И. Снегирева И., К. Затолочина Э., М. Дармостукова А., Р. Аляутдин Н., Б. Романов К. (2018) “Современные подходы к взаимозаменяемости вакцин // Modern approaches to vaccines interchangeability” / spz:neicon:vedomostincesmp:y:2016:i:4:p:3-8

12
CDC. A Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B Virus Infection in the United States. Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: Immunization of Adults. MMWR 2006; 55(RR16): 1–25. Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/ rr5516a1.htm.
(check this in PDF content)
13
Hamborsky J, Kroger A, Wolfe S, eds. CDC. Epidemiology and Prevention of Vaccine-Preventable Diseases. 13th ed. Washington D. C.: Public Health Foundation; 2015. Available from: http://www.cdc.gov/ vaccines/pubs/pinkbook/hepb.html.
(check this in PDF content)
18
Zueva LP, ed. Preventive vaccination in health facilities. St. Petersburg; 2004 (in Russian).
(check this in PDF content)
19
Ozeretskovsky NA, Shalunova NV, Petruchuk EM, Indikova IN. Vaccinoprophylaxis of viral hepatitis B. Epidemiologiya i vaktsinoprofilaktika 2015; (2): 87–95 (in Russian).
(check this in PDF content)
26
Zuckerman JN, Kirkpatrick CT, Huang M. Immunogenicity and reactogenicity of Avaxim (160 AU) as compared with Havrix (1440 EL. U) as a booster following primary immunization with Havrix (1440 EL. U) against hepatitis A. J Travel Med. 1998; 5(1): 18–22.
(check this in PDF content)
27
Bryan JP, Henry CH, Hoffman AG, South-Paul JE, Smith JA, Cruess D, et al. Randomised, cross-over, controlled comparison of two inactivated hepatitis A vaccines. Vaccine 2000; 19(7/8): 743–50.
(check this in PDF content)
28
Holzer BR, Hatz C, Schmidt-Sissolak D, Gluck R, Althaus B, Egger M. Immunogenicity and adverse effects of inactivated virosome versus alum-adsorbed hepatitis A vaccine: a randomised controlled trial. Vaccine 1996; 14(10): 982–6.
(check this in PDF content)
29
Holzer BR, Hatz C, Schmidt-Sissolak D, Gluck R, Althaus B, Egger M. Immunogenicity and adverse effects of inactivated virosome versus alum-adsorbed hepatitis A vaccine: a randomised controlled trial. Vaccine 1997; 15(2): 230–6.
(check this in PDF content)
42
Feldman S. Interchangeability of vaccines. Pediatr Infect Dis J. 2001; 20: 23–9.
(check this in PDF content)
43
Storsaeter J, Hallander HO, Gustafsson L, Olin P. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 1998; 16: 1907–16.
(check this in PDF content)
44
Taranger J, Trollfors B, Bergfors E, Knutsson N, Sundh V, Lagergård T, et al. Mass vaccination of children with pertussis toxoid: Decreased incidence in both vaccinated and nonvaccinated persons. Clin Infect Dis. 2001; 33: 1004–9.
(check this in PDF content)